Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Health Minister Asks for Consent to 30% Copayment Hike
May 27, 2002
- Kirindo to Boost Consolidated Sales to \67.5 Bil. in FY2004
May 27, 2002
- Approval No Longer Required for Pseudoephedrine HCl, Sulfate
May 27, 2002
- Cawachi: Ordinary Profits Up 34% to \9 Bil.
May 27, 2002
- Dissolution Tests Proposed for 15 Active Ingredients
May 27, 2002
- Greencross-coa: Strong Growth in Operating, Ordinary Profits
May 27, 2002
- JMARI Urged Gov't to Promote Proper Use of Antibiotics via Payment Incentives
May 20, 2002
- Denka Seiken: Influenza Vaccines Increase Sales by 19%
May 20, 2002
- On-line Medical Billing Studied by Korosho Group
May 20, 2002
- Denka Seiken Obtains FDA Approval for MRSA Detection Reagent
May 20, 2002
- GL on Treatment of Cerebral Infarctions
May 20, 2002
- Building Trust with Drs Is Important: Mr Bootes of Pfizer
May 20, 2002
- Draft RA Care Guidelines Presented: JRA
May 20, 2002
- JHSF Urges Makers to Beef Up Int'l Competitiveness in Genomic Drug Discovery
May 20, 2002
- WORLD NEWS IN BRIEF
May 20, 2002
- Trends in Informatics Reported by JHSF
May 20, 2002
- R&D Synergy to Accelerate Antibody Therapeutics: Chugai, Roche
May 20, 2002
- Increases in CAM-Resistant Hp Require Alternative Regimens
May 20, 2002
- Kumakura to Follow Path of His Predecessor: Kuraya Sanseido
May 20, 2002
- Epidural PCA Effective for Postoperative Pain
May 20, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…